Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of Anrikefon in Healthy Men
NCT05835934Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hsk21542 in postoperative pain and pruritus, sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Mass balance at 240 hours. Started Jun 2021; status: completed.
02
Drugs
hsk21542
03
Conditions
postoperative painpruritus
Beyond the preview
Go deeper on NCT05835934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835934.